The opioid-induced constipation market size has the potential to grow by USD 3.39 billion during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.
This report provides a detailed analysis of the market by route of administration (oral and parenteral), class of drugs (peripherally acting mu-opioid receptor antagonists, locally acting chloride channel activator, and others), and geography (North America, Europe, Asia, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., and Takeda Pharmaceutical Co. Ltd.
Market Overview
Browse TOC and LoE with selected illustrations and example pages of Opioid-Induced Constipation Market
Market Competitive Analysis
The market is concentrated. AstraZeneca Plc, Bausch Health Companies Inc., and Daiichi Sankyo Co. Ltd. are some of the major market participants. Although the increase in opioid prescriptions globally will offer immense growth opportunities, the use of conventional laxatives for opioid-induced constipation will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market position, this opioid-induced constipation market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this opioid-induced constipation market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading companies, including:
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Daiichi Sankyo Co. Ltd.
- Ironwood Pharmaceuticals Inc.
- Mallinckrodt Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- SHIONOGI Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
Opioid-Induced Constipation Market: Segmentation by Geography
For more insights on the market share of various regions Request for a FREE sample now!
North America will offer several growth opportunities to market vendors during the forecast period. Factors such as the high rate of use of opioid in the US will significantly drive opioid-induced constipation market growth in this region over the forecast period.
54% of the market’s growth will originate from North America during the forecast period. The US is a key market for opioid-induced constipation drugs in North America. Market growth in this region will be faster than the growth of the market in other regions.
Opioid-Induced Constipation Market: Segmentation by Type
Request for a FREE sample and Get more information on the market contribution of various segments
The opioid-induced constipation market share growth by the oral RoA segment will be significant during the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the opioid-induced constipation market size.
Opioid-Induced Constipation Market: Key Drivers and Trends
The increase in opioid prescriptions across the globe is one of the critical factors that will propel the opioid-induced constipation market’s growth in the next five years. There has been a massive increase in opioid prescriptions across the world for providing relief from pain caused by chronic diseases such as rheumatoid arthritis, endometriosis, fibromyalgia, inflammatory bowel disease (IBD), vulvodynia, and interstitial cystitis. The US has the highest rate of opioid use in the world, and the Canadian population also continues to suffer from disproportionate use of opioids.
The prescription of opioids has increased because physicians continue to prescribe them without considering the abuse and addiction-related side effects and opioid-induced constipation (OIC), which will boost the growth of the global opioid-induced constipation market. Also, the rise in cases of opioid-induced constipation among the elderly will drive the opioid-induced constipation market to grow at a CAGR of more than 21% during the forecast period.
Opioid-Induced Constipation Market: Key Highlights of the Report for 2020-2024
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will drive opioid-induced constipation market growth during the next five years
- Precise estimation of the opioid-induced constipation market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the opioid-induced constipation industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of opioid-induced constipation market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch